Journal of Antimicrobial Chemotherapy

J Antimicrob Chemother doi:10.1093/jac/dky038

Occurrence of the mobile colistin resistance gene *mcr-3* in *Escherichia coli* from household pigs in rural areas

Jiyun Li¹, Anette Hulth², Lennart E. Nilsson³, Stefan Börjesson⁴, Baoli Chen⁵, Zhenwang Bi⁵, Yang Wang¹, Stefan Schwarz^{1,6} and Congming Wu¹*

¹Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; ²Public Health Agency of Sweden, Stockholm, Sweden; ³Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; ⁴Department of Animal Health and Antimicrobial Strategies, National Veterinary Institute (SVA), Uppsala, Sweden; ⁵Shandong Center for Disease Control and Prevention, Jinan, China; ⁶Institute of Microbiology and Epizootics, Centre for Infection Medicine, Department of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany

*Corresponding author. Tel: +(8610)-62733378; E-mail: wucm@cau.edu.cn

Sir,

Polymyxins are regarded as one of the few last-resort antibiotics for the treatment of serious infections caused by MDR Gramnegative bacteria, such as carbapenem-resistant Enterobacteriaceae. However, the discovery of the plasmid-mediated colistin resistance gene mcr-1 further reduced the treatment options.¹ The gene *mcr-1* has been identified in Enterobacteriaceae from different sources in more than 45 countries on five continents.^{2,3} The gene mcr-2 was identified in Escherichia coli from pigs and cattle in Belgium.⁴ This gene is rarely detected and seems to be limited to some European countries. 4,5 Recently, the third plasmidmediated colistin gene, mcr-3, has been reported in China.⁶ The mcr-4 and mcr-5 genes have been newly identified in Enterobacteriaceae from animals and humans in European countries.^{7,8} The gene mcr-3 shares 45% and 47% nucleotide sequence identity with mcr-1 and mcr-2, respectively, and the corresponding protein shares 33% and 32% amino acid identity with MCR-1 and MCR-2, respectively. To date, the knowledge about the occurrence of mcr-3 genes in Enterobacteriaceae from humans or animals is still limited. Here, for the first time (to the best of our knowledge), we report the occurrence of *mcr*-3 in backyard pigs from households in rural areas of China.

We screened 417 pig faecal samples from 254 household backyard farms in 12 villages in the Shandong province in 2015, using ESwabs (Copan, Brescia, Italy). The faecal sample was first added

to 1 mL of Nutrient broth (Hangzhou Binhe Microorganism Reagent Co., Ltd, Hangzhou, China) and was incubated overnight at 37°C. Total DNA from 500 µL of the enrichment culture of each sample was extracted using the TIANamp Bacteria DNA Kit (TIANGEN Biotech Co., Beijing, China). The total DNA was screened for mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 genes by PCR as previously described.^{1,4,6-8} A total of 71 (71/417, 17%) samples from 56 households were positive for mcr-1. Five (5/417, 1.2%) samples from five households were positive for mcr-3. All samples were negative for mcr-2, mcr-4 and mcr-5. A 1 µL sample of each mcr-3positive culture was plated on Salmonella Shigella (SS) agar (Hangzhou Binhe Microorganism Reagent Co., Ltd) containing 2 mg/L colistin. Colonies with different morphology on the SS agar were picked and checked for the presence of the mcr-3 gene by PCR and sequencing. Five mcr-3-positive isolates, AZ20, BZ5, CZ11, LZ11 and IZ43, were detected from five different villages and all of them were identified as E. coli through 16S rDNA sequencing and MALDI-TOF MS analysis.² Testing for susceptibility to eight antimicrobial agents by agar dilution and confirmation by broth dilution^{9,10} revealed that all isolates were resistant to colistin and gentamicin, and isolates AZ20 and BZ5 were also resistant to ciprofloxacin. All isolates were susceptible to meropenem and intermediate to ceftazidime (Table 1).

DNA from the five *mcr-3*-positive strains was extracted using the TIANamp Bacteria DNA Kit. Paired-end sequencing was conducted using an Illumina HiSeq 2500 (Berry Genomic Company, Beijing, China). Reads were assembled *de novo* using SPAdes 3.9. The MLST profiles, putative plasmids and antibiotic resistance genes (Table 1) were predicted by uploading the assembly to the bacterial analysis pipeline at the Center for Genomic Epidemiology website (http://www.genomicepidemiology.org/). The *mcr-3* gene was identical in the three isolates CZ11, LZ11 and IZ43, whereas the amino acid sequence encoded by the *mcr-3* variant in isolates BZ5 and AZ20 differed from MCR-3 at three amino acid positions (M23V, A457E and T488I). This variant gene showed 100% nucleotide sequence identity to *mcr-3.5* (GenBank accession no. NG 055782). 12

S1-PFGE and Southern blot analysis revealed that mcr-3 and mcr-3.5 were located on different plasmids in the five isolates with their sizes ranging from \sim 83 to \sim 246 kb (Table 1). To test the transferability of the mcr-3 and mcr-3.5 genes, filter mating was performed with E. coli J53Az^R as recipient. ¹³ Transconjugants were selected on Brain Heart Infusion agar (Beijing Land Bridge Technology Ltd, Beijing, China) supplemented with 2 mg/L colistin and 300 mg/L sodium azide. Only isolates AZ20 and BZ5 carried conjugative plasmids, the IncP1-type plasmid pBZ5 and plasmid pAZ20 of an unknown Inc type. The two transconjugants exhibited 4- and 8-fold increased colistin and polymyxin B MICs compared with recipient E. coli J53, but were susceptible to the other six antimicrobial agents (Table 1). Electrotransformation was used for the remaining three mcr-3-carrying isolates. Two IncHI2 plasmids, pCZ11 and pLZ11, derived from isolates CZ11 and LZ11, respectively, were successfully transferred into E. coli DH5α (Takara Bio Inc., Beijing, China). The two transconjugants exhibited 16-fold

Table 1. Antimicrobial susceptibility and resistome profiles of the five mcr-3-/mcr-3.5-carrying strains and their transconjugants

		Variant and						MIC (r	MIC (mg/L) ^a				
Strain	MLST	size of <i>mcr-3-</i> carrying contig (kb)	Plasmid size (kb)	Plasmid type	CST	PMB	MEM	RIF	GEN	CIP	FFC	CAZ	Resistome profiles ^c
AZ20	ST155	mcr-3.5, 2.7	~83	unknown	%	4	0.008	4	256	32	128	4	aac(3)-IId, aadA1, aadA2, aph(3')-Ia, bla _{TEM-1B} , cmlA1, floR, fosA,
8Z5	ST165	mcr-3.5, 49.9	~91	IncP1	∞	4	0.016	7 94	32	4	∞	∞	oqxAB, qnrS2, strA, strB, sul2, sul3, tet(A) aac(G')Ib-cr, aadA1, aadA2, arr-3, bla _{TEM-1B} , cmlA1, dfrA12, oqxAB,
CZ11	ST3933	mcr-3, 2.6	~246	IncHI2	œ	∞	0.016	< > 2	128	0.5	4	2	qnrS2, sul3, tet(A) aph(3')-IIa, bla _{TEM-1B} , oqxAB, strA, strB, sul1,
LZ11	ST3933	mcr-3, 2.6	~246	IncHI2	∞	∞	0.016	<2	256	\leftarrow	4	∞	sul2, tet(A) aph(3')-IIa, bla _{TEM-1B} , oqxAB, strA, strB, sul1,
1243	ST10	mcr-3, 7.1	\sim 180	unknown	4	4	0.016	16	>256	0.25	∞	∞	sul2, tet(A) aac(6')Ib-cr, aacA4, aph(3')-Ic, arr-3, bla _{OXA-1} , bla _{TEM-1B} ,
													catB3, dfrA14, qnrS1, strA, strB, sul1, sul3, tet(A)
J53-AZ20 J53-BZ5	1 1	1 1	~83 ~91	unknown IncP1	8 4	7	0.008	4 4	~ ~	0.008	4 4	0.5	ON ON
J53 DH5α-CZ11 DH5α-LZ11 DH5α	1 1 1 1	1 1 1 1	1 1 1 1	- IncHI2 IncHI2 -	1 4 4 6 0.25	0.125	0.008	4 7 7 7	1 16 16	0.004	8 4 4 4	1 2 4	- N N I
3					24.0	24.0		1	2.0	7	-	7.0	

^aAbbreviations and resistance breakpoints: CST, colistin (R>2 mg/L); PMB, polymyxin B; MEM, meropenem (R≥4 mg/L); RIF, rifampicin; GEN, gentamicin (R≥16 mg/L); CIP, ciprofloxacin (R≥4 mg/L); FFC, florfenicol; CAZ, ceftazidime (R≥16 mg/L). CST: EUCAST interpretation criteria. MEM, GEN, CIP and CAZ: CLSI interpretation criteria. PMB, RIF and FFC: no interpretation

Bold formatting indicates resistance to the respective antimicrobial agents.

'GadA1, aadA2, aacA4, strA, strB, aac(3)-IId, aph(3')-Ia, aph(3')-Ia and aph(3')-Ic: aminoglycoside resistance genes. sul1, sul2 and sul3: sulphonamide resistance genes. dfrA12 and dfrA14: trimethoprim resistance genes. tet(A): tetracycline resistance gene. cm/A1, floR and catB3: phenicol resistance genes. blarEM-1B and bla_{OXA-1}: B-lactam resistance genes. fosA: osfomycin resistance gene. arr-3: rifampicin resistance gene. oqxAB, qnrS1, qnrS2 and aac(6')-Ib-cr. quinolone resistance genes. ND, not determined.

JAC

increased colistin and polymyxin B MICs and exhibited 64-fold increased gentamicin MICs compared with $E.\ coli\ DH5\alpha$ (Table 1). WGS analysis of the five mcr-3- and mcr-3.5-carrying isolates revealed contigs ranging in size from 2.6 to 49.9 kb (Table 1). The core structure, mcr-3-dgkA, was identified in all five contigs, four of which exhibited >99% nucleotide sequence identity to the corresponding region of the original mcr-3-carrying plasmid pWJ1. The largest contig (49.9 kb) of plasmid pBZ5 showed 99% nucleotide sequence identity to that in plasmid pMCR3_WCHEC-LL123 (GenBank accession no. MF489760) of human $E.\ coli$ from China. Plasmid pBZ5 contained toxin–antitoxin systems (higB and higA) as well as conjugative elements, which can maintain mcr-3.5 in its host and facilitate the horizontal transfer of this mcr-3 variant to other bacteria. 14

Two of the *E. coli* isolates (CZ11 and LZ11) had identical resistome profiles, the same MLST type (ST3933) and similar MIC values (Table 1). The Parsnp tool in the Harvest suite was applied to compare the homology of the mcr-3-positive isolates. ¹⁵ It revealed that the two isolates CZ11 and LZ11 were almost identical in their core-genome SNPs. The two *E. coli* isolates were from two different villages separated by a distance of \sim 10 km, suggesting a clonal spread of mcr-3-carrying isolates among pigs from different villages, possibly by trade of their respective animals.

In summary, this is—to the best of our knowledge—the first report of *mcr-3* and *mcr-3.5* in *E. coli* in backyard pig husbandry. This study revealed that *mcr* genes are not restricted to pigs from large-scale commercial farms, but also occur in pigs from small-scale backyard holdings. Therefore, adequate measures, such as raised awareness of rational usage of antimicrobial agents in both animals and humans, prudent usage of colistin in pigs for disease treatment and prevention, and good management/hygiene of backyard farming, should be taken into account to limit the spread of *mcr* genes, including *mcr-3* and its variants.

Funding

This study is part of the Sino-Swedish IMPACT project funded by the National Natural Science Foundation of China (grant 81361138021) and the Swedish Research Council (grant D0879801).

Transparency declarations

None to declare.

References

- 1 Liu YY, Wang Y, Walsh TR et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16: 161–8.
- **2** Wang Y, Zhang R, Li J *et al*. Comprehensive resistome analysis reveals the prevalence of NDM and MCR-1 in Chinese poultry production. *Nat Microbiol* 2017; **2**: 16260.
- **3** Schwarz S, Johnson AP. Transferable resistance to colistin: a new but old threat. *J Antimicrob Chemother* 2016; **71**: 2066–70.
- **4** Xavier BB, Lammens C, Ruhal R *et al.* Identification of a novel plasmid-mediated colistin-resistance gene, *mcr-2*, in *Escherichia coli*, Belgium, June 2016. *Euro Surveill* 2016; **21**: pii=30280.
- **5** AbuOun M, Stubberfield EJ, Duggett NA et al. mcr-1 and mcr-2 variant genes identified in Moraxella species isolated from pigs in Great Britain from 2014 to 2015. J Antimicrob Chemother 2017: **72**: 2745–9.
- **6** Yin W, Li H, Shen Y *et al*. Novel plasmid-mediated colistin resistance gene *mcr*-3 in *Escherichia coli. mBio* 2017; **8**: e00543-17.
- **7** Carattoli A, Villa L, Feudi C *et al*. Novel plasmid-mediated colistin resistance *mcr*-4 gene in *Salmonella* and *Escherichia coli*, Italy 2013, Spain and Belgium, 2015 to 2016. *Euro Surveill* 2017; **22**: pii=30589.
- **8** Borowiak M, Fischer J, Hammerl JA *et al.* Identification of a novel transposon-associated phosphoethanolamine transferase gene, *mcr*-5, conferring colistin resistance in *d*-tartrate fermenting *Salmonella enterica* subsp. *enterica* serovar Paratyphi B. *J Antimicrob Chemother* 2017; **72**: 3317–24.
- **9** EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 6.0, 2016.
- **10** Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fifth Informational Supplement M100-S25*. CLSI, Wayne, PA, USA, 2015.
- **11** Bankevich A, Nurk S, Antipov D *et al*. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 2012; **19**: 455–77.
- **12** Liu L, Feng Y, Zhang X *et al.* New variant of *mcr-3* in an extensively drugresistant *Escherichia coli* clinical isolate carrying *mcr-1* and *bla*_{NDM-5}. *Antimicrob Agents Chemother* 2017; **61**: e01757-17.
- **13** Pham Thanh D, Thanh Tuyen H, Nguyen Thi Nguyen T *et al.* Inducible colistin resistance via a disrupted plasmid-borne *mcr-1* gene in a 2008 Vietnamese *Shigella sonnei* isolate. *J Antimicrob Chemother* 2016; **71**: 2314–7.
- **14** Yang QE, Walsh TR. Toxin-antitoxin systems and their role in disseminating and maintaining antimicrobial resistance. *FEMS Microbiol Rev* 2017; **41**: 343–53.
- **15** Treangen TJ, Ondov BD, Koren S *et al.* The Harvest suite for rapid coregenome alignment and visualization of thousands of intraspecific microbial genomes. *Genome Biol* 2014; **15**: 524.